Nano-medicine is the foundation of our small molecule ULA platform and our next generation LNP delivery of gene-editing therapeutics.
Estimated infections in the US
Estimated infections worldwide
Annual drug sales in HIV category
Increase in healthcare costs for HIV+ vs HIV-
Patients are fully adherent to treatment
Prefer long-acting therapy to daily oral therapy
Risk-reduction when HIV PrEP is taken as prescribed
Exavir’s small molecule platform technology enables ultra-long-acting release for potentially once-every-six-months and longer dosing
HIV REVERSE TRANSCRIPTASE
Advances in precision gene-editing have enabled the possibility of a cure for HIV.
We are developing next generation nanoparticles for multiple gene-editing based strategies.
EXAVIR LIPID NANOPARTICLESRead More